hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06364033 id: CLL2624 briefTitle: Biological and Clinical Efficacy of Shingrix in Patients With CLL overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2025-11 date: 2028-10 date: 2024-04-15 date: 2024-04-15 name: Gruppo Italiano Malattie EMatologiche dell'Adulto class: OTHER briefSummary: This is a biological study. Patients who are eligible to receive Shingrix through the Italian National Health System will be invited to participate in the study. According to AIFA indication, the two doses of vaccine will be administered 4-8 weeks apart. Blood samples will be collected prior to the first vaccine dose (i.e. within the time frame of 3 months prior to the first dose) and 1, 6, 12, 24 and 36 months after the second vaccine dose to evaluate the serological response of Shingrix. conditions: Chronic Lymphocytic Leukemia conditions: Small Lymphocytic Lymphoma conditions: CLL-like MBL conditions: Varicella-zoster Virus Reactivation studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 312 type: ESTIMATED name: serologic response evaluation measure: Serologic response evaluation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UOC Ematologia ASST dei Sette Laghi city: Varese country: Italy name: Marta Coscia role: CONTACT lat: 45.82058 lon: 8.82511 hasResults: False
nctId: NCT06364020 id: APHP230067 briefTitle: Assessment of Risk Factors in Patients With Non-carious Cervical Lesions acronym: LACIS overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-15 date: 2024-04-15 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: In the management of patients with noncarious cervical lesions (NCCL), we observe that they frequently present signs of anxiety, traumatic brushing, bruxism or eating disorders. These multifactorial and interrelated etiologies make diagnosis and management difficult. Furthermore, in the literature, there is a lack of studies that evaluate the relationship between these risk factors and NCCL. A better understanding of the etiology and risk factors would help to optimize patient management and direct patients to the most appropriate therapies. conditions: Anxiety conditions: Stress conditions: Non-carious Cervical Lesions studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED measure: To investigate the association between anxiety/stress and the presence of NCCL. measure: To investigate the association between bruxism and the presence of NCCL. measure: To investigate the association between eating disorders and the presence of NCCL. sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Hôpital Rothschild - Service Odontologie city: Paris zip: 75012 country: France name: Caroline Mocquot, MCU-PH role: CONTACT phone: +33622971627 email: caroline.mocquot@aphp.fr name: Maria Clotilde Carra, Professor role: CONTACT phone: +33630746555 email: mariaclotilde.carra@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06364007 id: SLiu0401 briefTitle: HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC overallStatus: RECRUITING date: 2024-03-03 date: 2025-12-31 date: 2026-03-31 date: 2024-04-12 date: 2024-04-12 name: Sulai Liu class: OTHER briefSummary: The treatment options for unresectable HCC have rapidly developed, and immunotherapy has shown significant survival benefits in hepatocellular carcinoma. The STRIDE regimen of Single Tremelimumab (high, priming 300-mg dose) Regular Interval Durvalumab (1500 mg every 4 weeks) improved OS vs sorafenib in pts with unresectable HCC. In Asian region, HAIC is applied for HCC patients who are not suitable for surgical resection or local ablation treatment. Retrospective studies suggested a potent antitumor effect and survival benefit of HAIC plus programmed death-1 inhibitor and Lenvatinib. This phase II study was aimed to evaluate the efficacy and safety of STRIDE plus lenvatinib, given concurrently with HAIC in pts with unresectable HCC. conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: HAIC+STRIDE+Len measure: ORR measure: PFS measure: OS measure: DCR measure: AE sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hunan Provincial People's Hospital(The First Affiliated Hospital of Hunan Normal University) status: RECRUITING city: Changsha state: Hunan country: China name: Chuang Peng, PhD role: CONTACT phone: 15200850489 email: pengchuangcn@163.com lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06363994 id: ICP-CL-00128 briefTitle: A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL overallStatus: NOT_YET_RECRUITING date: 2024-05-25 date: 2034-12-25 date: 2035-12-25 date: 2024-04-12 date: 2024-04-12 name: InnoCare Pharma Inc. class: INDUSTRY briefSummary: Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL) conditions: Mantle Cell Lymphoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 490 type: ESTIMATED name: Orelabrutinib name: Bendamustine Injection name: Rituximab name: Orelabrutinib Placebo measure: Dose-limiting toxicity (DLT) measure: Progression-free Survival (PFS) for Arm A vs. Arm C sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06363981 id: JagiellonianU72 briefTitle: Multisite rTMS for Mood, Cognitive Impairment and Other Symptoms of Depression overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-12 date: 2027-04 date: 2024-04-12 date: 2024-04-15 name: Jakub Antczak class: OTHER name: Andrzej Frycz Modrzewski Krakow University briefSummary: Depressed mood is the main symptom of depression, but other symptoms like cognitive impairment, anhedonia or sleep disorders may also contribute to patients suffering and are difficult to treat. rTMS is a relatively novel treatment option, whose therapeutic potential is still investigated and optimized. The aim of this study is to assess the effect of rTMS applied over two stimulation sites on cognitive impairment, anhedonia and sleep disorders in depression. conditions: Unipolar Depression conditions: Bipolar Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment Prospective, randomized, sham-controlled clinical trial in parallel design primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Placebo intervention will be delivered with a programmable coil for magnetic stimulation, which can be switched by a third person between modes of active (therapeutic) and sham stimulation. In the sham-mode coil elicits similar sounds as in the active stimulation, but induces only negligible magnetic field. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: Active rTMS over the left DLPFC and over the left DMPFC name: Active rTMS over the left DLPFC name: Sham rTMS measure: Beck Depression Inventory 2 measure: Froward digit span measure: Language part of Addenbrooke's Cognitive Examination measure: Dimensional Anhedonia Rating Scale measure: Athens Insomnia Scale measure: Pittsburgh Sleep Quality Index measure: Epworth Sleepiness Scale sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Education of Research and Development Center, Babinski Clinical Hospital city: Cracovia zip: 30393 country: Poland name: Wojciech Korzeniowski, MD role: CONTACT phone: +48 12 652 42 00 email: wojciech.korzen@gmail.com name: Jakub Antczak, MD role: CONTACT phone: +48 12 25 50 email: jakub.antczak@uj.edu.pl lat: 50.06143 lon: 19.93658 hasResults: False
nctId: NCT06363968 id: 1743326 briefTitle: Biomarkers in the Retina for Prognosticating Mental Health Treatments acronym: BRIGHT overallStatus: RECRUITING date: 2024-02-12 date: 2025-09-01 date: 2030-09-01 date: 2024-04-12 date: 2024-04-12 name: VA Puget Sound Health Care System class: FED briefSummary: Title: ERG as a potential biomarker of SSRI-responsive PTSD: A pilot study
Posttraumatic stress disorder (PTSD) affects many individuals who experience a traumatic event. Previous studies suggest that there is a connection between the brain and the retina, and that the electroretinogram (ERG) may be a valuable biomarker to tell us more about signals in the brain that are related to mental health disorders like PTSD. The goal of this observational study is to examine the ERG waveform in veterans with PTSD before and after a single dose of the selective serotonin reuptake inhibitor (SSRI), sertraline. Sertraline is one of two FDA-approved medications for the treatment of PTSD. The main questions this pilot study aims to answer are:
Following the initial study visits, participants will enter an optional open label phase of the study in which qualifying participants who initiate antidepressant treatment through routine clinical care will be invited back for a follow-up ERG recording. conditions: PTSD conditions: Posttraumatic Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 50 type: ESTIMATED name: RETeval measure: ERG b-wave amplitude response to SSRI measure: Total Clinician Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; CAPS-5) score measure: Total PTSD Checklist for DSM-5 (PCL-5) sex: ALL minimumAge: 21 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VA Puget Sound Health Care System status: RECRUITING city: Seattle state: Washington zip: 98108 country: United States name: Rebecca C Hendrickson, MD, PhD role: CONTACT phone: 206-277-5054 email: rebecca.hendrickson@va.gov name: Katharine J Liang, MD, PHD role: SUB_INVESTIGATOR name: Rebecca C Hendrickson, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06363955 id: INTM-PMCF-UNIMOUTH id: 750/13.02.2023 type: OTHER domain: National and Kapodistrian University of Athens briefTitle: Assessing the Efficacy of a Hydrogen Peroxide Mouthwash for Oral Wound Healing, Oral Hygiene and Xerostomia Relief overallStatus: COMPLETED date: 2023-04-25 date: 2024-04-01 date: 2024-04-01 date: 2024-04-12 date: 2024-04-26 name: National and Kapodistrian University of Athens class: OTHER name: Ioulia And Irene Tseti Pharmaceutical Laboratories S.A. briefSummary: The aim of this study is to evaluate the efficacy and safety of a hydrogen carbamide/peroxide mouthwash, named UNISEPT® MOUTHWASH, regarding oral wound healing, postoperative symptoms, xerostomia (dry mouth) and oral hygiene improvement. Study participants have reported dry mouth and are scheduled for a diagnostic biopsy of minor labial salivary glands to investigate Sjögren's Syndrome, following consultation with their rheumatologist. This is a standardized diagnostic procedure that leads to healing by primary intention (i.e. wound edges are closely re-approximated with sutures).
Researchers are comparing this mouthwash with a placebo (a look-and-taste-alike substance that contains no active ingredients) to see if it is helpful with healing of wounds in the mouth and associated symptoms, improving dry mouth and/or oral hygiene. Participants randomly get the hydrogen carbamide/peroxide mouthwash or the placebo one to use for 14 days after the biopsy. The investigators will not know which one they are providing as the bottles will be identical.
Oral wound healing, postoperative symptoms (such as pain, eating and speech difficulties), oral hygiene (dental plaque and gingival inflammation), improvement of dry mouth and quality of life are assessed during a 14-day period after the biopsy. Participants are required to visit the clinic three times, one for the initial consultation and the biopsy, one at 7 days and one at 14 days after the biopsy. They are asked to fill in some questionnaires, while certain procedures (such as measuring saliva) and assessments (like evaluating the dental plaque and gingival inflammation) take place. During the first week they, also, keep a diary of their symptoms, as instructed. conditions: Wound Heal conditions: Oral Dryness conditions: Postoperative Pain conditions: Sjogren's Syndrome conditions: Biopsy Wound conditions: Mouth; Wound conditions: Mouth Dryness conditions: Dental Plaque conditions: Gingival Inflammation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This trial is designed as a prospective, randomized, placebo-controlled, triple blinded, with two parallel groups and an equal allocation ratio in all groups. In this study, the intervention consists of delivery of a hydrogen carbamide/peroxide mouthwash or placebo mouthwash, made by the same manufacturer. primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 54 type: ACTUAL name: Hydrogen Carbamide/Peroxide Mouthwash name: Placebo mouthwash measure: Assessment of wound healing based on the modified Landry Healing Index on day 14 measure: Assessment of wound healing based on a modified version of the Early Wound Healing Score (EHS) on day 14 measure: Assessment of wound healing based on the modified Landry Healing Index on day 7 measure: Assessment of wound healing based on a modified version of the Early Wound Healing Score (EHS) on day 7 measure: Postoperative symptoms (pain, eating and speech difficulty) during the first week (at home) measure: Postoperative symptoms (pain, eating and speech difficulty) on day 7 measure: Postoperative symptoms (pain, eating and speech difficulty) on day 14 measure: Wound healing based on the incision/wound length measure: Subjective oral dryness symptoms (8-item VAS questionnaire) measure: Observed (objective) signs of oral dryness measure: Change in Unstimulated Saliva Flow Rate measure: Oral Hygiene - Dental Plaque: Full-Mouth Plaque Index measure: Oral Hygiene - Gingival Inflammation: Full Mouth Gingival Index measure: Oral Health Related Quality of Life measure: Assessment of swelling in the biopsy area measure: Adverse Events measure: Participant's comments and satisfaction regarding the provided treatment/use of the products measure: Compliance sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Oral Medicine & Pathology and Hospital Dentistry, School of Dentistry, National and kapodistrian University of Athens city: Athens state: Attiki zip: 11527 country: Greece lat: 37.97945 lon: 23.71622 hasResults: False
nctId: NCT06363942 id: 2024-5973 briefTitle: A Personalized Video-based Exercise Program for Fall Prevention in Frail and Pre-frail Older Adult overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-04-15 date: 2026-04-15 date: 2024-04-12 date: 2024-04-12 name: McGill University Health Centre/Research Institute of the McGill University Health Centre class: OTHER briefSummary: This is a randomized interventional clinical trial, whereby 100 participants will be randomized to either follow the SAFE exercise program (experimental group) or not (control group). At the end of the intervention, the experimental group will be encouraged to continue doing the exercises, and the control group will have the opportunity to participate in the SAFE exercises. 12 weeks post-intervention, the investigators will follow up with participants by telephone to follow up whether they are still following the SAFE program or not. conditions: Fall Injury conditions: Frailty conditions: Old Age; Atrophy conditions: Age-Related Atrophy conditions: Age-Related Sarcopenia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: SAFE program (exercise intervention) measure: Objective 1 measure: Objective 2 measure: Objective 4 sex: ALL minimumAge: 70 Years stdAges: OLDER_ADULT facility: Royal Victoria Hospital - Glen site city: Montréal state: Quebec zip: H4A 3J1 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06363929 id: 341-23 briefTitle: Continuous Glucose Monitoring in Neonatal Hyperinsulinism overallStatus: RECRUITING date: 2023-06-01 date: 2025-06-01 date: 2025-12-31 date: 2024-04-12 date: 2024-04-12 name: MemorialCare Health System class: OTHER name: DexCom, Inc. briefSummary: The investigators are studying the accuracy of Dexcom G6 continuous glucose monitors placed on babies with hyperinsulinism in the Miller Children's Hospital Neonatal Intensive Care Unit. The participants will wear the device for 10 days on their lateral thigh. Whenever blood sugars are checked by glucometer, the investigators will also record the continuous glucose monitor sugar. Additionally, if the continuous glucose monitor alarms for a low sugar or an impending low sugar, the investigators will check the blood sugar by glucometer and, if verified to be low, treat the low blood sugar accordingly. conditions: Hyperinsulinism conditions: Hypoglycemia Neonatal studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 15 type: ESTIMATED name: Dexcom G6 continuous glucose monitor measure: Mean absolute relative difference (MARD) measure: Mean absolute difference (MAD) sex: ALL minimumAge: 24 Hours maximumAge: 3 Months stdAges: CHILD facility: Miller Children's Hospital status: RECRUITING city: Long Beach state: California zip: 90806 country: United States name: Erin Okawa role: CONTACT phone: 310-825-6244 email: eokawa@memorialcare.org lat: 33.76696 lon: -118.18923 hasResults: False
nctId: NCT06363916 id: 2023-A00335-40 briefTitle: Evaluation of Security and Efficacy of Medtrum Hybrid Closed Loop System acronym: SEECLOOP overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-11 date: 2025-12 date: 2024-04-12 date: 2024-04-12 name: Medtrum France class: INDUSTRY name: Axonal-Biostatem briefSummary: The purpose of this study is to evaluate the safety and effectiveness of the MEDTRUM Hybrid Closed Loop (HCL) System in children, adolescents, and adults with type 1 diabetes (7-75 years old) in a home setting and to test the function of meal announcement in an extend study.
nctId: NCT06363903 id: 2022-MMC-051 briefTitle: ASIA-Mesh: a Pilot Study for Diagnostics and Treatment on ASIA Syndrome Caused by Polypropylene Mesh Implantation overallStatus: RECRUITING date: 2022-05-09 date: 2024-05 date: 2025-05 date: 2024-04-12 date: 2024-04-12 name: Maxima Medical Center class: OTHER name: Amsterdam UMC name: Maastricht University Medical Center briefSummary: In the present pilot study, a possible relation between the implantation of PP mesh for inguinal hernia, vaginal prolapse and SUI repair and subsequent systemic auto-immune complaints is investigated by testing immunologic and allergic responses in fifty patients with suspected ASIA syndrome. Additional value of MAT is investigated and effectiveness of (partial) PP mesh removal for these complaints is assessed. If so, a profound insight in diagnostics and treatment for systematic complaints will be attained that may provide opportunities for future diagnostics. conditions: Autoimmunity conditions: Inguinal Hernia conditions: Stress Urinary Incontinence conditions: Pelvic Organ Prolapse conditions: Implant Complication conditions: Systemic Autoimmune Disease studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: mesh allergy test name: blood tests name: Mesh removal measure: Positive diagnostic tests measure: Autoimmune complaints and objective findings in immunologic blood test measure: Autoimmune complaints and objective findings in mesh allergy test (MAT) measure: Mesh removal and subjective complaints measure: Mesh histopathology measure: Patient demographics sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Maastricht University Medical Centre status: ACTIVE_NOT_RECRUITING city: Maastricht state: Limburg zip: 6229HX country: Netherlands lat: 50.84833 lon: 5.68889 facility: Maxima Medical Centre status: RECRUITING city: Veldhoven state: Noord-Brabant zip: 5504DB country: Netherlands name: Willem AR Zwaans, MD PhD role: CONTACT phone: +31408888550 email: willem.zwaans@mmc.nl name: Maurits JC Gielen, MD role: SUB_INVESTIGATOR lat: 51.41833 lon: 5.40278 facility: Amsterdam UMC status: NOT_YET_RECRUITING city: Amsterdam state: Noord-Holland zip: 1105AZ country: Netherlands name: Prof. Dr. J.P. Roovers role: CONTACT lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06363890 id: TD02 briefTitle: Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia acronym: AusTD overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-10-01 date: 2025-12-01 date: 2024-04-12 date: 2024-04-12 name: Lumen Bioscience, Inc. class: INDUSTRY briefSummary: The study proposed here will determine the frequency and etiology of diarrhea in Australian adult tourists traveling to Southeast Asia, including Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand, Timor-Leste, and Vietnam. The results from this study will inform the feasibility and design of subsequent clinical trials of travelers' diarrhea interventions in this population. conditions: Travelers Diarrhea studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 1200 type: ESTIMATED name: TAQMan Array Card measure: Characterize the frequency and etiology of travelers' diarrhea in this participant population of Australian adult tourists traveling to Southeast Asia. sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06363877 id: 5220078 briefTitle: Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-10 date: 2025-11 date: 2024-04-12 date: 2024-04-12 name: Loma Linda University class: OTHER briefSummary: This is a multicenter randomized controlled trial of 1100 patients to evaluate the superiority of combined intraoperative wound irrigation with intraoperative peritoneal lavage with dilute aqueous povidone-iodine compared to normal saline in male and female patients between the ages of 18 and 80 years old undergoing emergency laparotomies with Centers for Disease Control (CDC) class 2 and 3 wounds. conditions: Surgical Site Infection studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 1100 type: ESTIMATED name: Povidone-Iodine name: Normal Saline measure: Surgical Site Infection measure: Readmission measure: Return to the Operating Room measure: Ileus measure: Small Bowel Obstruction sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Loma Linda University Health city: Loma Linda state: California zip: 92354 country: United States name: Martin G Rosenthal, MD role: CONTACT email: mrosenthal@llu.edu name: Martin Rosenthal, MD role: PRINCIPAL_INVESTIGATOR name: Mohamed H El-Farra, MD role: SUB_INVESTIGATOR lat: 34.04835 lon: -117.26115 hasResults: False